BTIG Reiterates Buy Rating on Zevra Therapeutics

BTIG has reiterated its buy rating for Zevra Therapeutics, Inc. (NasdaqGS: ZVRA), maintaining a price target of $27. This update came on June 9, 2026, as the stock traded at $12.96.

Other Institutional Activity in Zevra Therapeutics

Several institutional investors have recently adjusted their positions in Zevra Therapeutics. BlackRock, Inc. reduced its holdings by 50,575 shares, leaving it with 4,456,476 shares valued at about $41.5 million. Woodline Partners LP made a minor addition of 99 shares, maintaining its stake at 3,450,943 shares worth approximately $32.2 million. Meanwhile, FMR LLC significantly increased its position by 818,384 shares, now holding 3,211,877 shares valued at $29.9 million. Nantahala Capital Management, LLC also added 750,000 shares, bringing its total to 2,521,936 shares valued at about $23.5 million. Vanguard Capital Management LLC made a new entry with 2,469,328 shares valued at $23.0 million.

Zevra Therapeutics Stock Snapshot

Shares of Zevra Therapeutics are trading at $12.96. The company has a market cap of approximately $747.8 million and a P/E ratio of 6.29. With a beta of 0.894, the stock has seen a 52-week low of $7.16 and a high of $14.27. The 50-day moving average is $10.71, and the 200-day moving average stands at $9.52. Zevra boasts a strong current ratio of 4.89 and a quick ratio of 4.736 with a debt-to-equity ratio of 0.557.

Recent Earnings

In its most recent earnings report, Zevra Therapeutics posted revenue of $122.3 million, reflecting a growth of 77.5%. The company's earnings per share (EPS) were $2.01, with a net margin of 101.6% and a return on equity (ROE) of 100.7%. The next earnings date is scheduled for May 6, 2026.

Insider Buying and Selling at Zevra Therapeutics, Inc.

Insider activity at Zevra Therapeutics has been notable. On May 28, 2026, Timothy Sangiovanni, SVP of Finance & Corporate Controller, purchased 40,000 shares. Rahsaan Thompson, Chief Legal & Compliance Officer, sold 1,794 shares on May 11, 2026, under a 10b5-1 plan. Earlier, on March 24, 2026, John Bode sold 78,400 shares and also bought the same amount at a price of $4.93.

Analysts Set New Price Targets

Several analysts have recently maintained their buy ratings for Zevra Therapeutics. On June 11, 2026, Canaccord Genuity set a price target of $29. Maxim Group followed on June 10, with a target of $35. Guggenheim also reiterated a $29 target on the same day. BTIG reaffirmed its $27 target on June 9, reflecting ongoing confidence in the stock's potential.

About Zevra Therapeutics

Zevra Therapeutics, Inc. is a biotechnology company headquartered in Boston, Massachusetts. It focuses on developing treatments for rare diseases, utilizing its Ligand Activated Technology platform. The company's lead product candidates include KP1077 for idiopathic hypersomnia and narcolepsy, and Celiprolol for vascular Ehlers-Danlos syndrome. Zevra also offers AZSTARYS for ADHD and OLPRUVA for urea cycle disorders, among others. Led by CEO Neil F. McFarlane, Zevra employs 61 people.

Bottom Line

BTIG's reiterated buy rating for Zevra Therapeutics underscores ongoing confidence in the company's growth potential. With a market cap nearing $748 million and a diverse product pipeline, Zevra remains a company to watch in the biotech sector. Institutional and insider activities highlight the interest surrounding this stock, but investors should remember that analyst ratings reflect opinions at a point in time and are not guarantees of future performance.